Merck & Co.

research deal two people shaking hands in lab

Merck opts in on Evaxian's preclinical vaccine candidate

Merck is licensing one of Evaxion’s AI platform-based vaccine candidates, offering the biotech up to $592 million for rights to the preclinical asset.

Gabrielle Masson Sep 25, 2025 7:00am

3D Rendering futuristic robot technology development artificial intelligence

Merck inks $349M biobucks deal to apply AI to tricky targets

Sep 23, 2025 7:00am

Numbers and boxes floating on a blue digital background

One-third of data collected in trials may be unnecessary: study

Sep 19, 2025 11:01am

HHS headquarters as seen on April 02 2025

Fierce Pharma

RFK Jr.'s ACIP delivers perplexing vote on MMRV vaccine guidance

Sep 18, 2025 6:33pm

Big Ben and Houses of Parliament On River Thames in London

Pharma execs grilled by UK lawmakers over R&D pullback

Sep 16, 2025 12:27pm

ABPI releases life sci competition report as UK investment lags

Sep 10, 2025 5:30pm